Trials & R&D · first seen 50m ago, updated 50m ago
Merck expands Welireg's use to broader set of kidney cancer patients
Merck’s Welireg won FDA approval on Friday for use in combination with Eisai’s Lenvima to treat certain kidney cancer patients. The combination will be available to patients with advanced renal cell carcinoma with a clear ...
Summary from Endpoints News.